Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-01-17

Clinical Trial Update: Comparison of Effectiveness and Safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in the Treatment of Melasma [NA]

View source ↗

Summary

This trial compares the effectiveness and safety of two triple-combination topical regimens for melasma: fluocinolone acetonide 0.01%/hydroquinone 4%/tretinoin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mometasone Furoate + Hydroquinone + Tretinoin combination cream (mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05%)
  • Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%)

Snippet

Sponsor: Indonesia University | Conditions: Melasma | NA | Status: NOT_YET_RECRUITING